mardi 3 avril 2018

Onco Actu du 3 avril 2018

1. Biologie

CRISPR paper that sent stocks tumbling is retracted [STAT]

The “interstitium”: Interesting science versus PR spin and pseudoscience [Respectful Insolence]

Metastatic Knowledge [The Scientist]

1.1 Biologie - Gènes

Scientists uncover “long tail” of nearly 100 genes mutated in prostate cancer [Broad Institute]

2.4 Etiologie - Portables, ondes e-m

The Nation indulges in fear mongering about cell phones and cancer [Science-Based Medicine]

Cell phones and cancer: random chance in clinical trials [Science-Based Medicine]

3.1.1 Prévention - Tabac - e-cigs

Devices to Quit Smoking Become the Devices Teenagers Can’t Quit [NY Times]

3.3 Prévention - Vaccins

HPV vaccine coverage on the rise, but still far from 2020 goal [Reuters]

Call to extend HPV vaccine to boys as cancer rates soar [The Guardian]

3.8 Prévention - Alimentation

Go ahead and drink your coffee, public health experts say [LA Times]

Give up coffee? Fuggedaboutit, say New Yorkers after California ruling [The Guardian]

4.10 Dép., diag. & prono. - Poumon

Robots Could Replace Surgeons in the Battle Against Cancer [Bloomberg]

4.5 Dép., diag. & prono. - Colorectal

Andrew Lansley calls for better NHS screening after revealing bowel cancer [The Guardian]

5.10 Traitements - Essais

NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials [NCI]

5.12.1 Immunothérapies - partenariats

AstraZeneca, Compugen sign immuno-oncology deal [FierceBiotech]

AZ signs up for access to Compugen’s pipeline [PharmaTimes]

5.12.5 Immunothérapies - Pharma

Dendreon chairwoman figures Provenge growth, infrastructure can pave its way into CAR-T [FiercePharma]

5.2 Pharma

The European Medicines Agency accepts regulatory submission for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer [AstraZeneca]

US FDA accepts Biologics License Application for moxetumomab pasudotox in hairy cell leukaemia [AstraZeneca]

In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data [EndPoints]

In sudden revamp, Celgene CEO Alles bids his COO goodbye and looks to regain confidence with management shuffle [EndPoints]

EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma [Sanofi]

5.3 Traitements - FDA, EMA, NICE...

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s efforts to enhance the patient perspective and experience in drug development and review [FDA]

5.3.4 Traitements - AMM (FDA, EMA,...)

Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint? [RAPS]

How long are delays in cancer drug approvals outside the U.S.? [Healthcare Economist]

5.4 Traitements - Economie

Senators launch probe into why price of cancer drug increased 1400 percent [The Hill]

Opinion on Innovative payment models for high-cost innovative medicines [European Commission]

6.1 Observation

Declines in Lung Cancer Death Rates Among U.S. Women Have Lagged in Two Hot Spots [AACR]

NHS trusts cancelled hundreds of cancer procedures over winter [The Guardian]

6.11 Patients

‘I was a caricature of my worst traits’ – how brain cancer can affect the mind [The Guardian]

6.5 Médecines alternatives

The deadly false hope of German alternative cancer clinics, part 3: Hallwang Clinic revisited [Respectful Insolence]

6.6 Publications

Cancer researcher at The Ohio State University resigns following multiple misconduct findings [Science]

Ohio State just released a 75-page report finding misconduct by a cancer researcher. What can we learn? [Retraction Watch]

French Universities Cancel Subscriptions to Springer Journals [The Scientist]

6.7.1 IA/bioinformatique

Emmanuel Macron wants France to become a leader in AI and avoid ‘dystopia’ [Science]

Emmanuel Macron Talks to WIRED About France's AI Strategy [Wired]